Domenico Acanfora1, Chiara Acanfora1, Pietro Scicchitano2, Marialaura Longobardi1, Giuseppe Furgi1, Gerardo Casucci3, Bernardo Lanzillo1, Ilaria Dentamaro2, Annapaola Zito2, Raffaele Antonelli Incalzi4, Marco Matteo Ciccone5. 1. Salvatore Maugeri Foundation I.R.C.C.S., Telese Terme, Benevento, Italy. 2. Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, School of Medicine, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy. 3. San Francesco Hospital, Telese Terme, Benevento, Italy. 4. Department of Geriatrics, Campus Bio-Medico University, Rome, Italy. 5. Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, School of Medicine, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy. marcomatteo.ciccone@uniba.it.
Abstract
BACKGROUND AND OBJECTIVES: The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodynamic profiles make them the optimal alternative to warfarin in the treatment of these two categories of patients. Unfortunately, however, NOACs cannot be used in patients with valvular AF or valvular cardiac prostheses. Although mechanical valves are effectively a contraindication to NOAC use due to several pathophysiological mechanisms that promote the use of warfarin rather than NOACs, few data exist regarding the use of such new pharmacological compounds on patients with cardiac biological valves or those who have undergone mitral repair or tubular aortic graft implantation. METHODS: Our case series involved 27 patients [mean age 70 ± 10 years; mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke/transient ischemic attack (doubled), Vascular disease, Age 65-74 years, Sex category): 6 ± 1.4; and mean HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios, Elderly, Drugs or alcohol): 4 ± 1] with AF and biological prostheses, repaired mitral valves, or tubular aortic graft who were treated with the factor Xa inhibitor rivaroxaban due to inefficacy or adverse effects of warfarin. RESULTS: The mean left ventricular ejection fraction was 48 ± 9 %, the left atrial diameter was 46.5 ± 7 mm, and the estimated glomerular filtration rate was 45 ± 21 mL/min/1.73 m(2). The mean duration of treatment was 15 ± 2 months. No relevant complications or recurrent thromboembolic events occurred. Three patients had recurrent nose bleeding and two had hematuria that led to reduction of the rivaroxaban dose by the treating physician to 15 mg once a day after 4 months of therapy. No further bleeding episode was recorded after escalating the dose. CONCLUSIONS: Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
BACKGROUND AND OBJECTIVES: The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodynamic profiles make them the optimal alternative to warfarin in the treatment of these two categories of patients. Unfortunately, however, NOACs cannot be used in patients with valvular AF or valvular cardiac prostheses. Although mechanical valves are effectively a contraindication to NOAC use due to several pathophysiological mechanisms that promote the use of warfarin rather than NOACs, few data exist regarding the use of such new pharmacological compounds on patients with cardiac biological valves or those who have undergone mitral repair or tubular aortic graft implantation. METHODS: Our case series involved 27 patients [mean age 70 ± 10 years; mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke/transient ischemic attack (doubled), Vascular disease, Age 65-74 years, Sex category): 6 ± 1.4; and mean HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios, Elderly, Drugs or alcohol): 4 ± 1] with AF and biological prostheses, repaired mitral valves, or tubular aortic graft who were treated with the factor Xa inhibitor rivaroxaban due to inefficacy or adverse effects of warfarin. RESULTS: The mean left ventricular ejection fraction was 48 ± 9 %, the left atrial diameter was 46.5 ± 7 mm, and the estimated glomerular filtration rate was 45 ± 21 mL/min/1.73 m(2). The mean duration of treatment was 15 ± 2 months. No relevant complications or recurrent thromboembolic events occurred. Three patients had recurrent nose bleeding and two had hematuria that led to reduction of the rivaroxaban dose by the treating physician to 15 mg once a day after 4 months of therapy. No further bleeding episode was recorded after escalating the dose. CONCLUSIONS:Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
Authors: Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: Alvaro Avezum; Renato D Lopes; Phillip J Schulte; Fernando Lanas; Bernard J Gersh; Michael Hanna; Prem Pais; Cetin Erol; Rafael Diaz; M Cecilia Bahit; Jozef Bartunek; Raffaele De Caterina; Shinya Goto; Witold Ruzyllo; Jun Zhu; Christopher B Granger; John H Alexander Journal: Circulation Date: 2015-06-23 Impact factor: 29.690
Authors: Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof Journal: Europace Date: 2013-05 Impact factor: 5.214
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Günter Breithardt; Helmut Baumgartner; Scott D Berkowitz; Anne S Hellkamp; Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf Journal: Eur Heart J Date: 2014-08-22 Impact factor: 29.983
Authors: Iqbal H Jaffer; Alan R Stafford; James C Fredenburgh; Richard P Whitlock; Noel C Chan; Jeffrey I Weitz Journal: J Am Heart Assoc Date: 2015-08-24 Impact factor: 5.501
Authors: Carlos F Lagos; Gerardine F Segovia; Nicolás Nuñez-Navarro; Mario A Faúndez; Flavia C Zacconi Journal: Molecules Date: 2017-09-22 Impact factor: 4.411
Authors: Fabián Santana-Romo; Carlos F Lagos; Yorley Duarte; Francisco Castillo; Yanina Moglie; Miguel A Maestro; Nitin Charbe; Flavia C Zacconi Journal: Molecules Date: 2020-01-23 Impact factor: 4.411